Europe Facial Injectable Market Share, Size, Trends, Industry Analysis Report, By Product (Collagen & PMMA Microspheres, Botulinum Toxin Type A, Hyaluronic Acid (HA), Calcium Hydroxylapatite (CaHA), Poly-L-lactic Acid (PLLA), and Others); By Application;

Europe Facial Injectable Market Share, Size, Trends, Industry Analysis Report, By Product (Collagen & PMMA Microspheres, Botulinum Toxin Type A, Hyaluronic Acid (HA), Calcium Hydroxylapatite (CaHA), Poly-L-lactic Acid (PLLA), and Others); By Application; By End-use; By Country; Segment Forecast, 2024 - 2032

The Europe facial injectable market size is expected to reach USD 7.33 billion by 2032, according to a new study by Polaris Market Research. The report “Europe Facial Injectable Market Share, Size, Trends, Industry Analysis Report, By Product (Collagen & PMMA Microspheres, Botulinum Toxin Type A, Hyaluronic Acid (HA), Calcium Hydroxylapatite (CaHA), Poly-L-lactic Acid (PLLA), and Others); By Application; By End-use; By Country; Segment Forecast, 2024- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Market expansion is due to an increase in awareness related to the benefits of facial injectables, innovation in facial injectables, and investments in the aesthetic industry. As individuals age, they experience various changes in their facial appearance, such as the development of wrinkles, fine lines, volume loss, and sagging skin. Facial injectables offer non-surgical solutions to address these signs of aging, providing patients with rejuvenated skin. As a result, the aging population is an additional factor driving the facial injectable market growth across European countries.

For instance, according to a report published by the World Health Organization (WHO), the European population aged 60 and older numbered 215 million in 2021 and is expected to reach 247 million by 2030.

Consumers are increasingly seeking alternatives to surgical treatments for changes in facial appearance. Moreover, key players operating in the facial injectable market are continuously developing new formulations and delivery techniques to improve the efficiency, safety, and longevity of injectable products. Hence, these advancements in cosmetic procedures have also contributed to the growing acceptance of dermal fillers among consumers, further driving growth.

A rise in cases of successful completion of clinical trials according to quality and safety standards will boost the demand for facial injectables, in turn increasing the market growth. For instance, in December 2023, Teoxane received a Medical Device Regulation (MDR) certification for its entire product portfolio. Similarly, in June 2023, Galderma received FDA approval for its newest hyaluronic acid filler, Restylane Eyelight. Also, in September 2023, Belotero Balance (+), manufactured by Merz Aesthetics, received FDA approval for the correction of moderate-severe facial wrinkles and folds.

The cost of these treatments may vary depending on the type of injectable used. For instance, according to the data published by the UK Health Centre, the cost of Juvederm starts at around USD 345 in the UK. Similarly, Restylane treatment costs between USD 250 – 500 in the UK. Thus, the high cost of these injectables is likely to deter the market growth. However, technological advancements have resulted in the development of affordable facial injectables without compromising their effectiveness.

Europe Facial Injectable Market Report Highlights

The Botulinum Toxin Type A segment will grow rapidly, attributed to its versatility, efficacy, and minimally invasive nature of the product.

The facial line correction segment held the largest revenue share, owing to the rapid growth of elderly population.

The MedSpa segment dominated the market due to the surge in demand for cosmetic procedures.

Germany dominated the market, owing to the rise in awareness related to the benefits of facial injectables.

Key players include Galderma, Merz GmbH, Revance Therapeutics, Ispen, Zimmer Aesthetics, AbbVie, Sinclair Pharma, and Teoxane.

Polaris Market Research has segmented the Europe facial injectables market report based on product, application, end-use, and country:

Europe Facial Injectable, Product Outlook (Revenue - USD Billion, 2019 - 2032)

Collagen & PMMA Microspheres

Botulinum Toxin Type A

Hyaluronic Acid (HA)

Calcium Hydroxylapatite (CaHA)

Poly-L-lactic Acid (PLLA)

Others

Europe Facial Injectable, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Facial Line Correction

Lip Augmentation

Face Lift

Acne Scar Treatment

Lipoatrophy Treatment

Others

Europe Facial Injectable, End-use Outlook (Revenue - USD Billion, 2019 - 2032)

MedSpa

Dermatology Clinics

Hospitals

Europe Facial Injectable, Country Outlook (Revenue - USD Billion, 2019 - 2032)

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe